Primary results from EMILIA, a phase III study of trastuzumab emtansine (T-DM1) versus capecitabine (X) and lapatinib (L) in HER2-positive locally advanced or metastatic breast cancer (MBC) previously treated with trastuzumab (T) and a taxane.
Kimberly Blackwell(Duke Medical Center), David Miles(Mount Vernon Cancer Centre), Luca Gianni, Ian E. Krop(Harvard University), Manfred Welslau, José Baselga(Harvard University), Mark D. Pegram(University of Miami), Do‐Youn Oh(Seoul National University Hospital), Véronique Dièras(Institut Curie), Steven R. Olsen, Fang Ting Liang, Michael W. Lu, Ellie Guardino, Sunil Verma(Sunnybrook Health Science Centre)
Cited by 83
Abstract
LBA1 The full, final text of this abstract will be available at abstract.asco.org at 12:01 AM (EDT) on Sunday, June 3, 2012, and in the Annual Meeting Proceedings online supplement to the June 20, 2012, issue of Journal of Clinical Oncology. Onsite at the Meeting, this abstract will be printed in the Sunday edition of ASCO Daily News.
Related Papers
No related papers found
Powered by citation graph analysis